Vimarsana
Biggest News Aggregation in the World

Mary Pak News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mary Pak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mary Pak Today - Breaking & Trending Today

Innovative Payment Models for Gene Therapies - Vimarsana News

Innovative Payment Models for Gene Therapies

Kimberly C. Chen, DO, MSHLM, discusses subscription models and warranties for cell and gene therapies, exploring their impact on patient access and financial sustainability.

Source: ajmc.com
Enhancing Collaboration for Patient-Centered Care in Rare Diseases - Vimarsana News

Enhancing Collaboration for Patient-Centered Care in Rare Diseases

A panel of experts discuss improving collaboration between health systems and managed care organizations to ensure optimal outcomes for patients with rare diseases.

Source: ajmc.com
Ethical Implications of Patient Access Restrictions - Vimarsana News

Ethical Implications of Patient Access Restrictions

Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.

Source: ajmc.com
Interpreting Clinical Data to Guide Coverage Decisions for Rare Disease Therapies - Vimarsana News

Interpreting Clinical Data to Guide Coverage Decisions for Rare Disease Therapies

Health care professionals discuss the challenges related to developing and interpreting clinical data for rare disease therapies to guide payer coverage decisions.

Source: ajmc.com
Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect - Vimarsana News

Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect

Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies.

Source: ajmc.com